Video Upload Options

References

1. Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick T, Brushaber D, Dheel C,Fields J, Forsberg L, Gavrilova R, Gearhart D, Graff-Radford J, Graff-Radford N, Jack CR Jr, Jones D, Knopman D, Kremers WK, Lapid M, Rademakers R, Ramos EM,Syrjanen J, Boxer AL, Rosen H, Wszolek ZK, Kantarci K. Trajectory of lobaratrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRIstudy. Neurobiol Aging. 2020 Apr;88:42-50. doi:10.1016/j.neurobiolaging.2019.12.004.
2. Hsiung GYR, Feldman HH. GRN Frontotemporal Dementia. 2007 Sep 7 [updated 2020 Feb 6]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K,Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2020. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK1371/
3. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A,Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L,Mikol J, Deramecourt V, Lejeune P, de la Sayette V, Belliard S, Vercelletto M,Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO,Dubois B, Brice A; French research network on FTD/FTD-MND. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging andgenetic study. Brain. 2008 Mar;131(Pt 3):732-46. doi: 10.1093/brain/awn012.
4. Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Guideline Watch(October 2014): Practice Guideline for the Treatment of Patients With Alzheimer'sDisease and Other Dementias. Focus (Am Psychiatr Publ). 2017 Jan;15(1):110-128.doi: 10.1176/appi.focus.15106.
5. Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY, Deverasetty S,Qin Y, van Blitterswijk M, Jackson J, Appleby B, Bordelon Y, Brannelly P,Brushaber DE, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Fields J, Fong J, Foroud T, Forsberg LK, Gavrilova R, Ghoshal N, Goldman J, Graff-Radford J,Graff-Radford N, Grant I, Grossman M, Heuer HW, Hsiung GR, Huey E, Irwin D,Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH,Kremers W, Kukull W, Litvan I, Ljubenkov P, Lungu C, Mackenzie I, Mendez MF,Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Shaw L, Syrjanen J, Tartaglia MC, Tatton N,Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wong B, Wszolek Z, Rademakers R,Boeve BF, Rosen HJ, Boxer AL; ARTFL/LEFFTDS consortium, Coppola G. Geneticscreening of a large series of North American sporadic and familialfrontotemporal dementia cases. Alzheimers Dement. 2020 Jan;16(1):118-130. doi:10.1002/alz.12011.
6. Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A, Heuer HW,Elahi FM, Ljubenkov PA, Dever R, Kornak J, Appleby B, Bove J, Bordelon Y,Brannelly P, Brushaber D, Caso C, Coppola G, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J,Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY,Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, KerwinDR, Knopman DS, Kraft R, Kremers WK, Kukull WA, Litvan I, Lucente D, Lungu C,Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF,Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R,Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, BoeveBF, Kramer JH, Rosen HJ; ARTFL/LEFFTDS consortium. Assessment of executivefunction declines in presymptomatic and mildly symptomatic familialfrontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.Alzheimers Dement. 2020 Jan;16(1):11-21. doi: 10.1016/j.jalz.2019.01.012.
7. Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, Clark CM, Neumann M,Kwong LK, Trojanowski JQ, Lee VM, Grossman M. Clinical, genetic, and pathologiccharacteristics of patients with frontotemporal dementia and progranulinmutations. Arch Neurol. 2007 Aug;64(8):1148-53.
8. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. LancetNeurol. 2008 Oct;7(10):965-74. doi: 10.1016/S1474-4422(08)70194-7.
9. Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, Galloway NM, Feldman H, Woltjer R, Miller CA, Wood EM, Grossman M, McCluskey L, Clark CM,Neumann M, Danek A, Galasko DR, Arnold SE, Chen-Plotkin A, Karydas A, Miller BL, Trojanowski JQ, Lee VM, Schellenberg GD, Van Deerlin VM. The spectrum ofmutations in progranulin: a collaborative study screening 545 cases ofneurodegeneration. Arch Neurol. 2010 Feb;67(2):161-70. doi:10.1001/archneurol.2009.328.